Across 2021–2023, COVID-19 vaccines generated at least $140–$160 billion in global sales, led by Pfizer/BioNTech and Moderna.
If you’ve wondered, “how much money did COVID-19 vaccines make?”, here’s the clear picture: industry sales peaked in 2021–2022 and then cooled fast in 2023 as demand shifted from mass priming to seasonal boosters. Below, you’ll see where the dollars came from, how the biggest brands stacked up, and what the totals look like across the main years of the rollout.
Fast Context: Where The Revenue Came From
Vaccine dollars came from two waves. First, the 2021–2022 surge when governments pre-bought huge volumes. Second, the 2023 shift to smaller, variant-targeted boosters at higher per-dose prices but lower volume. A market tracker estimated ~US$60B in global sales for 2021 and a similar ~US$60B for 2022, before a drop in 2023. That already places the two-year tally near US$120B, even before counting 2020’s early rollout and 2023’s booster season.
How Much Money Did COVID-19 Vaccines Make? By Company
Here’s a broad, side-by-side look at the makers that reported the largest vaccine revenue during the peak years. To avoid double counting, note that Pfizer’s Comirnaty sales include doses jointly developed with BioNTech; BioNTech also reports its share separately as revenue from the partnership.
| Company / Brand | Peak Year Vaccine Revenue (USD) | Notes / Source |
|---|---|---|
| Pfizer (Comirnaty) | $36.8B in 2021; $37.8B in 2022; ~$11.2B in 2023 | Company filings and summaries; 2023 brand sales ranked ~$11.2B in an independent roundup; company 2022 report links to brand details. Sources: FiercePharma, Nature top-selling drugs 2023, Pfizer annuals. |
| BioNTech (partner to Pfizer) | €18.98B (2021); €17.3B (2022); ~€3.8B (2023) | Reported revenues from Comirnaty profit-share and related items. Source: BioNTech annuals, 2023 results. |
| Moderna (Spikevax) | $17.7B (2021); $18.4B (2022); ~$6.8B (2023) | Company reports and press coverage. Sources: Moderna annuals, Reuters. |
| AstraZeneca (Vaxzevria) | ~$4.1B (2021) | Sold at not-for-profit early on; revenue tailed off later and product has been withdrawn. Sources: Pharmaceutical Technology, FT on withdrawal. |
| Johnson & Johnson (Jcovden) | ~$2.39B (2021) | Priced on a not-for-profit basis; limited share later. Sources: Axios, J&J results. |
| Sinovac (CoronaVac) | ~$19.4B (2021 sales) | Company disclosure for full-year 2021. Source: Sinovac 2021 results. |
| Novavax (Nuvaxovid) | ~$2.0B (2022) | Company year as first broad commercial season. Sources: Novavax IR, press release. |
| Sinopharm (CNBG) | Large national supply; revenue embedded in group filings | Wide output; detailed 2021–2023 figures live in Chinese-language filings. Source: Sinopharm reports. |
The Best Single-Brand Snapshot
On a single-product basis, Pfizer’s Comirnaty set records. Reported brand sales reached $36.8B in 2021 and $37.8B in 2022, then cooled to about $11.2B in 2023 as the mass-dose phase ended and boosters became seasonal. Those totals come from company reports and independent tallies of the top-selling drugs list. Sources: FiercePharma; Nature’s 2023 sales roundup.
Close Variant: Money Made By COVID-19 Vaccines Worldwide — Big Picture
To build a clean total, start with the market-wide view and then layer in brand detail:
- 2021: global COVID-19 vaccine sales around US$60B. Source: Airfinity.
- 2022: again about US$60B worldwide per the same tracker.
- 2023: lower volume, higher per-dose prices, and a sharp decline vs. peak years. Single-brand reads show Comirnaty ~$11.2B and Spikevax ~$6.8B for 2023; adding the rest puts the year well above US$20B overall. Sources: Nature, Reuters.
Add the peak years (2021 + 2022 ≈ US$120B) and the cooler 2023 season (≥US$20B). That places the 2021–2023 total at US$140B+. Include late-2020 launch revenue and 2024’s modest booster income, and the lifetime haul climbs further.
What Pushed The Totals So High In 2021–2022?
Three levers mattered most: advance purchase agreements, rapid manufacturing scale-up, and tiered, country-by-country pricing. Government pre-buys locked in volume early. Manufacturing scaled to billions of doses. Prices varied by market and product, with mRNA brands carrying higher price points. WHO’s market review shows COVID-19 shots dominated vaccine volumes in 2022, even as non-COVID programs recovered. Source: WHO Global Vaccine Market Report.
Brand-Level Trends You Should Know
Pfizer/BioNTech
Mass global supply, premium pricing in many contracts, and the fastest bivalent/monovalent refresh cycle helped Comirnaty book the largest brand revenue. Company filings confirm a steep reset in 2023 as booster demand narrowed. Sources: Pfizer annuals, BioNTech 2023.
Moderna
Spikevax revenue hit $17.7B in 2021 and $18.4B in 2022, then slid to about $6.8B in 2023. The company has kept revenue flowing with updated boosters and signed supply deals, but volumes are thinner than the peak years. Sources: Moderna annuals, Reuters.
AstraZeneca
Vaxzevria fed the early global rollout, including huge shipments to lower-income markets at non-profit pricing. Revenue was far below the mRNA leaders and later dropped off; the product is now withdrawn. Sources: Pharmaceutical Technology, FT.
Johnson & Johnson
Priced at a not-for-profit level early on; 2021 sales were ~US$2.39B with lower figures later as supply shifted to other options. Sources: Axios, J&J.
China’s Producers (Sinovac, Sinopharm)
Sinovac reported ~US$19.4B in 2021 sales on CoronaVac, reflecting heavy domestic and international demand that year. Sinopharm’s vaccine output was large as well, with revenue integrated into broader group reports. Sources: Sinovac 2021, Sinopharm reports.
Totals You Can Use Right Now
To place all brands on one line, it helps to pin the two peak years to firm external estimates, then add 2023 from brand-level disclosures. That gives a conservative, defensible range for the period most readers care about.
| Year | Estimated Global COVID-19 Vaccine Sales | Basis / Source |
|---|---|---|
| 2021 | ~US$60B | Market estimate for the year. Source: Airfinity. |
| 2022 | ~US$60B | Market estimate; broadly the same as 2021. Source: Airfinity. |
| 2023 | ≥US$20B | Brand reads: Comirnaty ~$11.2B; Spikevax ~$6.8B; others add several billion. Sources: Nature, Reuters. |
Roll those together and the answer to “how much money did COVID-19 vaccines make?” lands at US$140–$160B for 2021–2023 alone, with 2020 and 2024 adding several billion more on top.
Why The Drop After 2022?
By 2023, most people who wanted a primary series had it. Booster intent softened, country orders moved from bulk government buys to smaller seasonal plans, and variant-matched shots narrowed the addressable pool. Pfizer and Moderna still logged meaningful revenue, but at a smaller base than the early surge.
How Pricing And Access Shaped The Money
mRNA brands commanded higher prices, while vector and inactivated vaccines often followed tiered pricing. AstraZeneca and J&J set non-profit terms early in the rollout. China’s producers supplied vast numbers of doses across Asia and Latin America. WHO’s market review adds helpful context on volumes and supply concentration across manufacturers. Source: WHO Global Vaccine Market Report.
Reading The Company Numbers Without Double Counting
One common pitfall: adding Pfizer’s Comirnaty sales and BioNTech’s revenue lines as if both were separate market sales. In reality, those records reflect two sides of the same product partnership (Pfizer reports brand sales; BioNTech reports its share). When you add up the market, use either the brand sales from Pfizer or the partner split from BioNTech, not both.
What This Means For 2024–2025 And Beyond
The market has settled into a booster rhythm with much smaller totals than the peak. Brands still update to match new lineages, but the main revenue story sits in 2021–2022. That’s the core of the “how much money did COVID-19 vaccines make?” question.
Methods And Sources At A Glance
- Market-level: Two peak-year estimates from a specialist tracker (~US$60B each for 2021 and 2022). Source: Airfinity.
- Brand-level: Company annual reports and press releases for Pfizer, BioNTech, Moderna, AstraZeneca, J&J, Sinovac, Novavax (linked throughout).
- Cross-checks: WHO’s Global Vaccine Market Report for volumes and concentration; independent 2023 brand sales roundup from Nature; 2023 Spikevax revenue from Reuters.
Key Takeaways
- Peak money sat in 2021–2022: roughly US$120B for those two years alone.
- 2023 cooled fast: still in the tens of billions, but far smaller than the surge years.
- Two brands led the pack: Comirnaty and Spikevax carried most of the global revenue.
- Do not double count: Pfizer’s and BioNTech’s lines reflect the same product partnership.
Bottom Line
When readers ask, “how much money did COVID-19 vaccines make?”, the grounded answer is: well over US$140B across 2021–2023, with Pfizer/BioNTech and Moderna as the main revenue drivers and a long tail from other suppliers. The exact figure shifts by method and currency, but the scale is clear in the linked filings and market reads above.